Anti-PD-L1 treatment significantly reduced tumor burden (Fig. 4e, f) and reversed the downward trend of CD8+PD-1+CD161+ T cells in the T region, while for CD8+PD-1+CD161− T cells, it reduced the enrichment degree in T region (Fig. 4g, h). This evidence concerns the gene CD8A and neoplasm.